FindTrial
Sign In

Fasting in managment of psoriasis

Efficacy of intermittent fasting in management of moderate to severe chronic plaque psoriasis - a phase 2b clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029472
Enrollment
120
Registered
2020-12-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Intermittent fasting (16: 8) : Intermittent fasting 16 hours fasting and 8 hours feeding Calorie unrestricted Control Intervention1: methotrexate: Methotrexate per orally 0.3 mg/Kg/ we

Sponsors

IADVL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Chronic plaque psoriasis candidate for systemic therapy Body surface area >10% or PASI >10 or DLQI >10

Exclusion criteria

Exclusion criteria: Contraindication to methotrexate or fasting pregnancy, lactation Uncontrolled diabetes mellitus Chronic infection like tuberculosis

Design outcomes

Primary

MeasureTime frame
Improvement in psoriasis assessment severity assessment (PASI)Timepoint: 12 weeks and 24 weeks—

Secondary

MeasureTime frame
Biomarkers for atherosclerosis HDL, CCRP, IL-6, VEGFTimepoint: 28 weeks;metabolic parameters Weight Waist size Blood sugar fasting and post prandial lipid profileTimepoint: 16 weeks, 28 weeks—

Countries

India

Contacts

Public ContactShekhar Neema

Armed Forces medical college

shekharadvait@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026